Vivus commercial chief takes a hike after slew of exec exits

Since bungling the launch of obesity drug Qsymia, Vivus ($VVUS) has lost more than half its board, its CFO, two CEOs and 20 staffers. Now, the company's chief commercial officer is following his departed colleagues out the door. Friday, the company said in a regulatory filing that Michael Miller would make his exit on Feb. 14, with CEO Seth Fischer taking over his responsibilities. 8-K | More

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.